口服依托泊苷治疗默克尔细胞癌。
Oral etoposide in Merkel cell carcinoma.
作者信息
Betancor Tatiana, Viña Maria Micaela, Ramos Sara, Cabrera Miguel Angel, Merino Francisco Javier
机构信息
Pharmacy Department, University Hospital Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain.
Oncology Department, University Hospital Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain.
出版信息
Eur J Hosp Pharm. 2017 Jul;24(4):244-245. doi: 10.1136/ejhpharm-2016-001194. Epub 2017 May 4.
BACKGROUND
Merkel cell carcinoma (MCC) is a very infrequent and aggressive skin tumor with high recurrence and metastasis rates. MCC treatment is currently not well defined.
CASE PRESENTATION
We present the case of a 75-year-old woman who was diagnosed with MCC in 2010 and suffered a third relapse in 2012 which could not be treated surgically.
RESULTS
The patient began oral etoposide treatment reaching complete response after eight cycles and receiving a total of 11 cycles. As side effects, the patient suffered from neutropenia, candidiasis and mucositis, but after reducing the dosage to 50% it was well tolerated.
DISCUSSION
Chemotherapy treatment in this setting is poorly defined. In this case, monotherapy treatment with oral etoposide was decided due to the patient's age and comorbidities, achieving a very positive outcome.
背景
默克尔细胞癌（MCC）是一种非常罕见且侵袭性强的皮肤肿瘤，复发率和转移率很高。目前MCC的治疗方法尚不明确。
病例报告
我们报告一例75岁女性患者，该患者于2010年被诊断为MCC，并于2012年第三次复发，无法进行手术治疗。
结果
患者开始口服依托泊苷治疗，八个周期后达到完全缓解，共接受了11个周期的治疗。作为副作用，患者出现了中性粒细胞减少、念珠菌病和粘膜炎，但将剂量减少至50%后耐受性良好。
讨论
这种情况下的化疗治疗尚不明确。在本病例中，由于患者的年龄和合并症，决定采用口服依托泊苷单药治疗，取得了非常积极的效果。
Zotero 插件